文献速递甲状腺疾病

甲状腺结节球形度指标可区分良性与恶性滤泡性及嗜酸细胞性肿瘤

Thyroid Nodule Sphericity Metrics Discriminate Benign and Malignant Follicular and Oncocytic Neoplasms.
PubMed 文献 · Thyroid · 2025-02-25

本研究在两个学术医疗系统回顾性分析1110个甲状腺结节的超声高宽比(TTW)特征与球形度指标,比较良性滤泡性/嗜酸细胞性腺瘤与滤泡性甲状腺癌(FTC)、嗜酸细胞性甲状腺癌(OCA)等。结果显示TTW在多数良恶性比较中无统计学差异,而球形度指数与球形度比在除嗜酸细胞性肿瘤外的大多数良恶性比较中有显著差异。

要点

  • TTW在滤泡性/嗜酸细胞性腺瘤与FV-PTC、OCA、FTC、NIFTP比较中无统计学差异(χ2,p=0.08,敏感度28%[CI 23-24%])。
  • 良性及恶性肿瘤作为一组比非肿瘤性结节更常见TTW(χ2,p=0.02)。
  • 球形度指数与球形度比在除嗜酸细胞性肿瘤外的大多数良恶性比较中有显著差异(Wilcoxon,p<0.03)。

核心结论

  • TTW形状在区分良性滤泡性与嗜酸细胞性肿瘤与恶性方面效用有限。
  • TTW在良恶性肿瘤作为一组与非肿瘤性结节比较时更常见,提示该超声特征可能是肿瘤性生长(良性或恶性)的指标而非癌症指标。
  • 作者认为需要球形度测量等替代方法来区分良性与恶性嗜酸细胞性及滤泡性肿瘤。

研究设计与样本

  • 本研究为回顾性研究,在两个学术医疗系统进行,分析放射科医师报告的TTW超声特征及结节球形度指标。
  • 从企业数据仓库提取良性及恶性滤泡性与嗜酸细胞性肿瘤、非肿瘤性结节(增生性及腺瘤样)及经典型甲状腺乳头状癌(PTC)的手术病理报告。
  • 独立复核每份超声并记录结节尺寸,以识别TTW结节并判断不同组织学良恶性结节中TTW比例是否不同,同时评估球形度指数与球形度比。
  • 共分析1110个结节:非肿瘤性结节209个(增生性及腺瘤样)、良性肿瘤398个(滤泡性及嗜酸细胞性腺瘤)、恶性肿瘤503个(FTC、OCA、PTC、滤泡亚型PTC[FV-PTC])及非浸润性甲状腺滤泡性肿瘤伴乳头状样特征(NIFTP)。

主要发现

  • 滤泡性及嗜酸细胞性腺瘤与FV-PTC、OCA、FTC、NIFTP比较时TTW无统计学差异(χ2,p=0.08,敏感度28%[置信区间23-24%])。
  • 滤泡性腺瘤与FTC比较时TTW无统计学差异(χ2,p=0.64)。
  • 嗜酸细胞性腺瘤与OCA比较时TTW无统计学差异(χ2,p=0.08)。
  • 良性及恶性肿瘤作为一组比非肿瘤性结节更常见TTW(χ2,p=0.02)。
  • 球形度指数与球形度比在除嗜酸细胞性肿瘤外的大多数良恶性结节比较中有显著差异(Wilcoxon,p<0.03)。

关键数值与推荐

  • TTW在滤泡性及嗜酸细胞性腺瘤与FV-PTC、OCA、FTC、NIFTP比较中:χ2,p=0.08,敏感度28%(置信区间23-24%)。
  • 滤泡性腺瘤与FTC比较:χ2,p=0.64。
  • 嗜酸细胞性腺瘤与OCA比较:χ2,p=0.08。
  • 良性及恶性肿瘤与非肿瘤性结节比较:χ2,p=0.02。
  • 球形度指数与球形度比在除嗜酸细胞性肿瘤外的大多数良恶性比较中:Wilcoxon,p<0.03。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: We investigated if thyroid nodule taller-than-wide (TTW) feature and sphericity metrics are helpful in separating benign neoplastic thyroid nodules (follicular and oncocytic adenomas) from follicular thyroid carcinomas (FTC) and oncocytic thyroid carcinomas (OCA). Methods: This is a retrospective study of TTW sonographic feature as reported by radiologists and nodule sphericity metrics at two academic health systems. Surgical pathology reports for benign and malignant follicular and oncocytic neoplasms, non-neoplastic nodules (hyperplastic and adenomatoid), and classic papillary thyroid cancers (PTC) were extracted from enterprise data warehouses. We independently reviewed each ultrasound and recorded nodule dimensions to identify nodules that were TTW and determine if the proportion of TTW nodules is different in benign and malignant thyroid nodules of various histologies. We also evaluated the sphericity index and sphericity ratio, two quantitative measures of how close the 3D shape of the nodule is to a sphere. Results: In total, 1110 nodules were analyzed: 209 non-neoplastic nodules (hyperplastic and adenomatoid), 398 benign neoplasms (follicular and oncocytic adenomas), and 503 malignant neoplasms (FTC, OCA, PTC, and follicular variant-PTC [FV-PTC]) and noninvasive follicular thyroid neoplasm with papillary-like features (NIFTP). There was no statistical difference for the TTW feature when follicular and oncocytic adenomas were compared with FV-PTC, OCA, FTC, and NIFTP (χ2, p = 0.08, sensitivity of 28% [confidence interval 23-24%]), when follicular adenoma was compared with FTC (χ2, p = 0.64) or when oncocytic adenoma was compared with OCA (χ2, p = 0.08). Benign and malignant neoplasms were more likely than non-neoplastic nodules to be TTW (χ2, p = 0.02). In contrast, the sphericity index and sphericity ratio were significantly different in most comparisons of benign and malignant nodules (Wilcoxon, p < 0.03) except for oncocytic tumors. Conclusions: TTW shape has limited utility in distinguishing benign follicular and oncocytic neoplasms from malignancy. This sonographic feature was more common among all benign and malignant neoplasms when they were compared as a group to non-neoplastic nodules, which suggests this sonographic feature is an indicator of neoplastic growth (benign or malignant) but not cancer. Alternative methods, such as measures of sphericity, are needed to distinguish benign and malignant oncocytic and follicular neoplasms.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Bell C, White SL, Tylee T, et al. Thyroid Nodule Sphericity Metrics Discriminate Benign and Malignant Follicular and Oncocytic Neoplasms. Thyroid. 2025. PMID: 39992747. doi:10.1089/thy.2024.0670

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。